Earnings
Novo Nordisk Q3 Sales Surge on GLP-1 Meds Amid Manufacturing Queries
Since the FDA gave the green light to Novo Nordisk’s GLP-1 weight-loss medication Wegovy over two years ago, the drug ...
Regeneron’s High-Dose Eylea Launch Takes Off, Rivals Roche’s Vabysmo
Roche’s increased sales for its extended-release treatment for macular degeneration, Vabysmo, indicate that consumers are willing to try new therapies. ...
AbbVie CEO reveals why it passed on Daiichi’s cancer drug
AbbVie CEO Rich Gonzalez has revealed the company’s stance on the recent ADC transaction involving Daiichi and Merck. Despite being ...
ResMed to cut 5% of workforce amid fiscal challenges
As ResMed seizes opportunities in the CPAP machine market, left open due to Philips’ ongoing respiratory device recall issues, the ...
3M CEO updates on healthcare spinoff amid revenue decline
In a recent company update, 3M has provided insights into the status of its long-anticipated healthcare business spinout, indicating that ...
Roche unveils its blood cancer strategy after COVID-19 boost
While Roche has seen a decline in COVID-19 drug sales after the pandemic boom, the company is experiencing a resurgence ...
Novo Nordisk raises its 2023 outlook for sales and profit, driven by strong diabetes and obesity drugs
Novo Nordisk is experiencing a remarkable surge in its fortunes, primarily driven by the widespread popularity of its diabetes medication ...
CDMO Experiences Downturn at Merck KGaA as COVID-Related Sales Plunge, Says CFO
Merck KGaA is facing the challenges it anticipated for 2023, with its contract manufacturing division and process solutions arm experiencing ...
AstraZeneca Expects Higher China Sales, Denies Spinoff Report
AstraZeneca’s CEO Pascal Soriot has denied a report that the company is considering spinning off its China business, which is ...
